{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:54:57Z","timestamp":1790384097663,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Center Research and Development","award":["28-A-21"],"award-info":[{"award-number":["28-A-21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Thymic epithelial tumors are a rare type of neoplasm. Accordingly, it is difficult to perform phase III trials in patients with thymic epithelial tumors, and thus, no standard treatment has been established for these tumors. In this study, we aimed to investigate the current status of thymic epithelial tumor treatment in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective observational study enrolled patients with thymic epithelial tumor whose data were recorded in a nationwide Hospital-based Cancer Registry that was linked with health insurance claims data for the registered patients between 2012 and 2014. The patients\u2019 treatment details were obtained from a health insurance claims database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 813 patients with thymoma and 547 with thymic carcinoma were included in the analysis. Overall, 549 (67.5%) thymoma patients underwent surgical resection alone. Among patients with thymic carcinoma, 230 (42.0%) underwent initial surgery, and 124 (53.9%) received subsequent radiotherapy and chemotherapy. Chemotherapy regimens varied across the hospitals; overall, 21 and 22 regimens were used to treat thymoma and thymic carcinoma, respectively. Platinum-based combination regimens were predominantly selected for both diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study revealed the real-world patterns of thymic epithelial tumor treatment in Japan. Although the nature of this study did not enable the determination of optimal treatment strategies, the simultaneous analysis of nationwide registry, insurance, efficacy and prognostic data may contribute to the establishment of a standard treatment strategy for rarely occurring cancers such as thymic epithelial tumor.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyz167","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T19:30:55Z","timestamp":1570563055000},"page":"310-317","source":"Crossref","is-referenced-by-count":10,"title":["Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012\u20132014"],"prefix":"10.1093","volume":"50","author":[{"given":"Hiroaki","family":"Kanemura","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke\u2019s International Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tamura","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke\u2019s International Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishimura","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke\u2019s International Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Epidemiology, St. Luke\u2019s International University Graduate School of Public Health, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"first","affiliation":[{"name":"Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"2020030903371850700_ref1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lungcan.2003.09.022","article-title":"Multimodal management of stages III-IVa malignant thymoma","volume":"44","author":"Bretti","year":"2004","journal-title":"Lung Cancer"},{"key":"2020030903371850700_ref3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"2020030903371850700_ref4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtcvs.2015.08.034","article-title":"Multimodality therapy for locally advanced thymomas: a propensity score-matched cohort study from the European Society of Thoracic Surgeons database","volume":"151","author":"Leuzzi","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2020030903371850700_ref5","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","article-title":"The role of chemotherapy in advanced thymoma","volume":"5","author":"Schmitt","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/JTO.0b013e318207cd74","article-title":"Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons","volume":"6","author":"Ruffini","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jtho.2016.11.2219","article-title":"Thymic carcinoma management patterns among international thymic malignancy interest group (ITMIG) physicians with consensus from the thymic carcinoma working group","volume":"12","author":"Shepherd","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref8","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1097\/JTO.0b013e3181f20e90","article-title":"Induction therapy for locally advanced thymoma","volume":"5","author":"Riely","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ctrv.2011.11.010","article-title":"State-of-the-art classification and multimodality treatment of malignant thymoma","volume":"38","author":"Koppitz","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"2020030903371850700_ref11","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.athoracsur.2004.12.047","article-title":"Advanced stage thymomas and thymic carcinomas: results of multimodality treatments","volume":"79","author":"Lucchi","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"2020030903371850700_ref12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2011.10.004","article-title":"Multimodal treatment for stage IVA thymoma: a proposable strategy","volume":"76","author":"Rena","year":"2012","journal-title":"Lung Cancer"},{"key":"2020030903371850700_ref13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.semtcvs.2004.11.003","article-title":"Role of chemotherapy in the management of advanced thymic tumors","volume":"17","author":"Evans","year":"2005","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2020030903371850700_ref14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","article-title":"The management of thymoma: a systematic review and practice guideline","volume":"4","author":"Falkson","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.athoracsur.2015.04.059","article-title":"Surgical outcomes of patients with stage III thymoma in the Japanese nationwide database","volume":"100","author":"Yamada","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2020030903371850700_ref16","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2020030903371850700_ref18","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"2020030903371850700_ref19","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"2020030903371850700_ref20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cas.12837","article-title":"Monitoring and evaluating the quality of cancer care in Japan using administrative claims data","volume":"107","author":"Iwamoto","year":"2016","journal-title":"Cancer Sci."},{"key":"2020030903371850700_ref21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jjco\/hyt013","article-title":"The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan","volume":"44","author":"Higashi","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2020030903371850700_ref22","volume-title":"International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)","author":"World Health Organization","year":"2000"},{"key":"2020030903371850700_ref23","volume-title":"TNM Classification of Malignant Tumours (UICC)","author":"Sobin","year":"2009","edition":"7th"},{"key":"2020030903371850700_ref24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10147-017-1178-y","article-title":"The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan","volume":"23","author":"Tsukada","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2020030903371850700_ref25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref26","volume-title":"SEER Summary Staging Manual","author":"Young","year":"2001"},{"key":"2020030903371850700_ref27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"2020030903371850700_ref28","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"2020030903371850700_ref29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"2020030903371850700_ref30","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2020030903371850700_ref31","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(15)00305-8","article-title":"Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial","volume":"16","author":"Shukuya","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020030903371850700_ref32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/jjco\/hyt106","article-title":"Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma","volume":"43","author":"Hirai","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2020030903371850700_ref33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3999\/jscpt.45.59","article-title":"Analysis of the situation of new indication approvals based on \u201cKouchi-shinsei\u201d and consideration of measures for its effective utilization","volume":"45","author":"Furukawa","year":"2014","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"2020030903371850700_ref34","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020030903371850700_ref35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020030903371850700_ref36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020030903371850700_ref37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020030903371850700_ref38","volume-title":"Classification of Tumours. Pathology and Genetics of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2004","edition":"3rd"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/3\/310\/32854146\/hyz167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/3\/310\/32854146\/hyz167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T07:37:38Z","timestamp":1583739458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/3\/310\/5673756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz167","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,12,12]]}}}